Nomination period for the Broermann Medical Innovation Award started
17.1.2025 12:17:33 CET | news aktuell GmbH | Press release
Prize money of one million euros higher than the prize money for the Nobel Prize for Medicine
Award honors researchers worldwide who have done pioneering work in medicine, biotechnology, or related fields
Gießen, January 17, 2025. The nomination period for the Broermann Medical Innovation Award has started. The prize, which will be awarded for the first time this year, is aimed at scientists worldwide who have carried out pioneering work in medicine, biotechnology, or related fields with their research.
The nomination portal (www.broermann-award.org/nomination/) is open until March 1, 2025. At one million euros, the prize is more valuable than the Nobel Prize for Medicine, making it one of the most highly endowed awards for medical research worldwide.
The international Broermann Medical Innovation Award recognizes research results that demonstrate a high level of innovation for clinical application and thus have the potential to improve the lives and health of millions of people worldwide. The prize is aimed at scientists whose research has been pioneering in the fields of medicine, biotechnology, or related sciences.
The Broermann Medical Innovation Award was established in 2024 to honor the vision and commitment of Dr. Bernard große Broermann, the founder of the Asklepios Kliniken. The Broermann gemeinnützige GmbH sponsors the award, and the University Hospital Giessen and Marburg (UKGM) manages the organization. “With this award, we want to honor groundbreaking medical discoveries and highlight those whose research brings real improvements in the prevention or treatment of diseases,” says Prof. Werner Seeger, Chairman of the Award Committee. For the Medical Director of the UKGM, Prof. Friedrich Grimminger, the unique prize reflects the clear conviction of the company founder: “Scientific excellence in medicine is always an international team effort, but without the genius of individual researchers, networks are limited in their impact. These key players and drivers of medical innovation should be promoted and recognized worldwide.”
Nomination process and deadlines
Nominations for the Broermann Medical Innovation Award can be submitted until March 1, 2025. The incumbent Hessian Minister President will present the award in December 2025 at the Hessian State Chancellery in Wiesbaden.
Further information on the award, the nomination criteria, and the selection process can be found at www.broermann-award.org.
For further information, please contact
Broermann Medical Innovation Award
Mirjam Malko
Tel.: +49 (0) 641 / 985-42310
E-Mail: contact@broermann-award.org
Asklepios Kliniken
Corporate Communications and Marketing
Tel.: + 49 (0) 40 / 18 18-82 66 36
E-Mail: presse@asklepios.com
24-hour on-call service for the press office: +49 (0) 40 / 1818-82 8888
Visit Asklepios on the Internet, Facebook or YouTube:
www.asklepios.com
www.asklepios.com/konzern/gesundheitsmagazin
www.facebook.com/asklepioskliniken
www.youtube.com/asklepioskliniken
RHÖN-KLINIKUM AG
Corporate Communications and Marketing
Heike Ochmann
Press Spokeswoman
Tel.: +49 (0) 9771 / 65-12130
E-Mail: heike.ochmann@rhoen-klinikum-ag.com
MEDICLIN AG
Dr. Janina Lossen
Press Spokeswoman
Tel:. +49 (0) 781 / 488-180
E-Mail: presse@mediclin.de
UKGM
Frank Steibli
Head of Communications and Press Spokesman
Tel.: +49 (0) 641 / 985-51020
Mobile: +49 (0) 160 / 7120456
E-Mail: frank.steibli@uk-gm.de
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Valle Venia presents new song by LPS feat. Lara: Where will it take me27.2.2026 10:15:00 CET | Press release
The song describes the challenge of trusting the flow, relying on oneself, following one's own values with confidence.
Vyoma awarded ESA data procurement contract for space-based data on small space debris24.2.2026 10:53:34 CET | Press release
(Munich, February 24th, 2026) Vyoma, a Munich-based company providing Space Domain Awareness (SDA) capabilities, has been selected as the winner of the ESA tender on ”Data Procurement for Space-Based Statistical Data on Small Space Debris Phase 1”, funded via ESA‘s Space Safety Programme (S2P). ESA’s Meteoroid And Space debris Terrestrial Environment Reference (MASTER) model provides a description of the space environment around Earth, supporting satellite designers, operators and others with risk assessments. Currently, there exists a significant temporal and spatial knowledge gap for observations of space debris with sizes smaller than the detection limit of ground-based sensors. Vyoma's Flamingo-1 satellite is ideally positioned to generate the image data ESA is seeking. Flying “in-situ” at an altitude of 510 km, Flamingo-1's instrument can monitor large volumes of space at once. This sensor detects objects at long and short distances and captures small and fast objects reliably, im
Medi-Globe Launches mAI Companion® — the World’s First Real Time AI Assistant for Pancreatic EUS, Co Developed with IHU Strasbourg —Now MDR CE Marked and Available for Clinical Use in Europe24.2.2026 10:00:00 CET | Press release
Rohrdorf (Achenmühle), Germany — February 24, 2026 — Medi-Globe today announced the launch of mAI Companion®, a real-time medical AI solution designed to assist physicians in detecting pancreatic lesions during endoscopic ultrasound (EUS) — addressing one of the deadliest and most difficult-to-detect cancers, where earlier identification can dramatically change patient outcomes.
Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect24.2.2026 08:43:52 CET | Press release
Aachen, Germany & Victoria, Australia, 24 February 2026 – Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a topical, non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain. Under the agreement, Clinect will be responsible for obtaining marketing authorisation for Qutenza® in Australia and, upon approval, marketing and distributing the product in Australia.
Clean energy needs a clean planet: PLAN-B NET ZERO and everwave launch joint initiative20.2.2026 13:26:02 CET | Press release
(Berlin, Germany) A strong start to 2026. PLAN-B NET ZERO enters into a partnership with the Aachen-based environmental scale-up everwave. With the guiding principle ‘1 euro = 1 kilogram of waste’, the partners recovered 10,000 kilograms of waste from rivers in Cambodia at the start of the initiative Around 11 million tonnes of plastic waste enter the oceans every year. Without effective countermeasures, this volume could almost triple by 2040. Studies show that about 80 percent of marine plastic reaches the sea via roughly 1,656 rivers worldwide. To date, everwave has removed more than 2.4 million kilograms of plastic from rivers in Cambodia, Albania, and Thailand. The company uses waste collection boats, barriers, and manual cleanups to stop plastic before it reaches the oceans. At the same time, mobile sorting and recycling solutions return materials efficiently to the circular economy. AI support optimizes collection routes to clean as many waterways as possible in a sustainable wa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom